Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?

Ono, Takaaki

doi:10.3390/cancers13205116

Cited by 14 publications

(7 citation statements)

References 65 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These treatment modalities are suitable for chronic CML. Several studies have shown that switching from imatinib to 2G–TKI shortened the time between DMR and TFR, so some studies have suggested the use of 2GTKI as a first–line treatment option for female patients with CML–CP who desire pregnancy ( 28 ). This view needs further validation because of the increased cost of 2G–TKI, the severe side effects, and the lack of extensive clinical data.…”

Section: Discussionmentioning

confidence: 99%

Management of Chronic Myeloid Leukemia and Pregnancy: A Bibliometric Analysis (2000-2020)

Wang

Jiang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundGiven the increasing number and survival rates of reproductive-age patients with chronic myeloid leukemia (CML), several studies aimed to elucidate optimum disease management in pregnancy. This study aimed to use bibliometric analysis to assess focus and reported insights, as well as future trends, in CML and pregnancy research.MethodsWe extracted all studies related to CML and pregnancy from the Web of Science database from 2001 to 2020. VOS Viewer, CiteSpace, Python, and R-bibliometrix were used for bibliometric analysis, revealing the leading research countries, institutions, and authors, as well as distribution of keywords (frequency greater than five).ResultsA total of 196 records, published in 137 journals by 1,105 authors from 421 research institutes in 50 countries, were identified for analysis. The United States was the leader in the number of publications. Imperial College London and National Research Center for Hematology were the most influential institutions. In addition, Apperley J, Cortes J, Abruzzese E and Kantarjian H were the leading authors in the field. Keyword analysis identified four research hotspot clusters.ConclusionsThis study systematically analyzed the progress in CML and pregnancy research in the last 20 years. The present findings suggest that the management of planned and unplanned pregnancies in patients with CML will remain a research focus, as further evidence is required for the development of treatment guidelines.

show abstract

Section: Discussionmentioning

confidence: 99%

Management of Chronic Myeloid Leukemia and Pregnancy: A Bibliometric Analysis (2000-2020)

Wang

Jiang

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

show abstract

“…Identifying appropriate patient candidates, timing of treatment initiation or dose adjustment, and consideration of numerous patient factors, including disease risk, molecular factors, efficacy and tolerability of prior treatments, patient age, comorbidities, and individual patient goals, are all crucial. 93 …”

Section: Considerations For Patient Selection For Asciminibmentioning

confidence: 99%

Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes

Hijiya,

Mauro

2023

CMAR

View full text Add to dashboard Cite

Tyrosine kinase inhibitors (TKIs) have significantly changed the treatment of chronic myeloid leukemia (CML) and improved outcomes for patients with CML in chronic phase (CML-CP) and accelerated phase (AP). Now armed with numerous effective therapeutic options, clinicians must consider various patient- and disease-specific factors when selecting the most appropriate TKI across lines of therapy. While most patients with CML expected to have a near-normal life expectancy due to the success of TKIs, emphasis has expanded beyond response and survival to include factors like quality of life, tolerability, and long-term toxicity management. Importantly, a subset of patients can achieve sustained deep molecular response and can attain treatment-free remission. Despite these successes, unmet needs remain related to CML treatment, including the persistent challenge of treatment resistance and intolerance, broadening treatment options for patients with resistance mutations or serious comorbidities, and focus on specific populations such as children and young adults. In particular, the only previously available treatments for patients with CML-CP with the T315I mutation were ponatinib, olverembatinib (exclusively approved for use in China at the time of this writing), omacetaxine, and hematopoietic stem cell transplantation. Asciminib has entered the CML treatment landscape as a new option for adult patients with CML-CP who have received ≥2 prior TKIs or those with the T315I mutation. Asciminib’s unique mechanism of action, Specifically Targeting the ABL Myristoyl Pocket, sets it apart from traditional adenosine triphosphate-competitive TKIs. While asciminib may overcome unmet needs for patients with CML-CP and continues to be studied in other novel settings, guidance on how to integrate asciminib in treatment algorithms is needed. This review focuses on clinical data and how asciminib can overcome current unmet needs, discusses how to individualize patient selection, and highlights future directions to investigate asciminib in earlier lines of therapy and in children and adolescents.

show abstract

“…Specifically, they are associated with cardiovascular, pulmonary, pancreatic, and hepatic toxicities [3]. In the ENESETnd study, 10-year cumulative incidence of cardiovascular events was 24.8% in the nilotinib (300 mg bid) arm as opposed to 6.3% in the imatinib arm [7]. Nilotinib is also associated with glucose tolerance and dyslipidemia, and its use in patients with cardiovascular risk factors or diabetes requires careful consideration.…”

Section: Second-generation-tkis Have No Survival Benefit But Have Gre...mentioning

confidence: 99%

Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm

Walia

Prasad

2023

Blood Cancer J.

View full text Add to dashboard Cite

Which Tyrosine Kinase Inhibitors Should Be Selected as the First-Line Treatment for Chronic Myelogenous Leukemia in Chronic Phase?

Cited by 14 publications

References 65 publications

Management of Chronic Myeloid Leukemia and Pregnancy: A Bibliometric Analysis (2000-2020)

Management of Chronic Myeloid Leukemia and Pregnancy: A Bibliometric Analysis (2000-2020)

Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes

Current CML guidelines overemphasize second generation TKIs: revisiting the paradigm

Contact Info

Product

Resources

About